A rare case presentation of gastrointestinal stromal tumor (GIST) in a young adult patient

Gastrointestinal stromal tumors (GISTs) are common primary mesenchymal neoplasms in the gastrointestinal tract. Although they account for less than 1 % of all GI tumors, high-risk or cancerous GISTs make up 20 % to 30 % of all cases. GISTs mostly affect people over 50 years old, with symptoms including bowel obstruction, constipation, GI bleeding, dysphagia, jaundice, and urination problems in males. KIT is highly expressed in GISTs, but tyrosine kinase inhibitors (TKI) such as imatinib, sunitinib, regorafenib, and ripretinib can target these tumors effectively. The therapy of GIST metastases in the liver is controversial, and metastatic liver disease is a significant factor in determining patient survival. Early detection and timely treatment can significantly improve the patient's prognosis and increase their chances of survival.